Skip to content

Analysis of Influencing Factors on the Effectiveness of Stellate Ganglion Block in Treating Insomnia Disorder and Construction of a Personalized Prediction Model

Analysis of Influencing Factors on the Effectiveness of Stellate Ganglion Block in Treating Insomnia Disorder and Construction of a Personalized Prediction Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114306
Enrollment
Unknown
Registered
2025-12-10
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

The SGB-effective group:None
The SGB-ineffective group:None

Sponsors

The 988th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for Insomnia Disorder as defined by the *International Classification of Sleep Disorders, Third Edition (ICSD-3); (2) Aged 18-70 years, with no restrictions on gender; (3) Pittsburgh Sleep Quality Index (PSQI) total score >= 7, with a duration of insomnia >=3 months; (4) Absence of other sleep disorders (e.g., sleep apnea syndrome, periodic limb movement disorder) confirmed by polysomnography (PSG); (5) Previous conservative treatments (e.g., cognitive behavioral therapy, pharmacotherapy) were ineffective or combination therapy is required; (6) Scheduled to undergo SGB treatment; (7) Voluntary provision of signed informed consent by the patient.

Exclusion criteria

Exclusion criteria: (1) Presence of severe cardiac, hepatic, or renal dysfunction, or coagulation disorders; (2) Previous history of SGB treatment; (3) Allergy to local anesthetics or vasoactive drugs; (4) Presence of cervical spine deformity, cervical infection, or severe cervical spondylosis; (5) Schizophrenia or other severe psychiatric disorders; (6) Pregnancy or lactation; (7) Inability to cooperate with follow-up procedures.

Design outcomes

Primary

MeasureTime frame
PSQI improvement rate post-treatment;Insomnia symptom remission rate;

Secondary

MeasureTime frame
Insomnia Severity Index;

Countries

China

Contacts

Public ContactErliang Kong

The 988th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army

kel1992@126.com+86 139 1750 6501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026